{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:31:01Z","timestamp":1791462661948,"version":"4.3.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Ivosidenib is a novel oral inhibitor of mutated isocitrate dehydrogenase 1 approved for the treatment of refractory or relapsed acute myeloid leukemia in patients with isocitrate dehydrogenase 1 mutations or as first-line agent in patients unable to tolerate chemotherapy. It is known to commonly cause differentiation syndrome, but an association with cardiovascular complications is not well established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We present the case of a 34-year-old female with relapsed acute myeloid leukemia post-allogeneic transplant who developed ivosidenib-induced differentiation syndrome complicated by myopericarditis and cardiogenic shock.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Management and outcome<\/jats:title>\n                    <jats:p>Ivosidenib was discontinued, and aggressive management was pursued with high-dose steroids, ventilatory and pressure support and diuresis. She had significant improvement and later tolerated reintroduction of ivosidenib without recurrent episodes of differentiation syndrome or cardiac complications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>To the best of our knowledge, this is the first reported case of myopericarditis and cardiogenic shock related to ivosidenib use. This case highlights the high index of suspicion required to recognize early signs of targeted therapy-related complications and exemplifies the beneficial collaborative role a cardio-oncology team provides in improving patient care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155219865934","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T21:15:12Z","timestamp":1565039712000},"page":"754-757","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Ivosidenib induction therapy complicated by myopericarditis and cardiogenic shock: A case report and literature review"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2576-3675","authenticated-orcid":false,"given":"Paula","family":"Hernandez Burgos","sequence":"first","affiliation":[{"name":"Morsani College of Medicine, University of South Florida, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaymin","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Morsani College of Medicine, University of South Florida, Tampa, FL, USA"},{"name":"Moffitt Cancer Center, Tampa, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,8,5]]},"reference":[{"key":"bibr1-1078155219865934","doi-asserted-by":"crossref","unstructured":"Norsworthy K, Luo L, Hsu V, et\u00a0al. FDA approval summary: ivosidenib for relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-1 mutation.\n                      Clin Cancer Res\n                      2019; 25: 3205\u20133209.","DOI":"10.1158\/1078-0432.CCR-18-3749"},{"key":"bibr2-1078155219865934","unstructured":"Agios receives FDA breakthrough therapy designation for TIBSOVO\u00ae (ivosidenib) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation in adult patients ineligible for intensive chemotherapy [Press Release]. Cambridge, MA: Agios Pharmaceuticals, Inc. 26 March 2019."},{"key":"bibr3-1078155219865934","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0978-3"},{"key":"bibr4-1078155219865934","first-page":"288","volume":"132","author":"Norsworthy K","year":"2018","journal-title":"Food and Drug Administration (FDA). Blood"},{"key":"bibr5-1078155219865934","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2016.04.006"},{"key":"bibr6-1078155219865934","doi-asserted-by":"publisher","DOI":"10.4250\/jcu.2011.19.2.95"},{"key":"bibr7-1078155219865934","doi-asserted-by":"crossref","unstructured":"Kota V, Clemmons A, Chand A, et\u00a0al. Congestive heart failure during induction with anthracycline-based therapy in patients with acute promyelocytic leukemia.\n                      J Community Support Oncol\n                      2014; 12: 390\u2013393.","DOI":"10.12788\/jcso.0084"},{"key":"bibr8-1078155219865934","first-page":"27","volume":"2","author":"Maqsood K","year":"2013","journal-title":"J Hematol"},{"key":"bibr9-1078155219865934","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr10-1078155219865934","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.179361"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219865934","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219865934","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219865934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:21:40Z","timestamp":1777688500000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219865934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,5]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1177\/1078155219865934"],"URL":"https:\/\/doi.org\/10.1177\/1078155219865934","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,5]]}}}